新型重组禽痘疫苗对墨西哥近期H7N3高致病性禽流感病毒的功效
研究用两种重组禽痘病毒疫苗接种鸡,三周后以2015年墨西哥H7N3高致病性禽流感病毒攻毒。含2015年H7血凝素基因的rFPV-H7/3002疫苗提供100%保护,显著减少呼吸道和胃肠道排毒;而含2002年H7基因的rFPV-H7/2155疫苗无效。结果表明需频繁更新疫苗种子株以应对抗原漂移。
要点
- rFPV-H7/3002对2015年墨西哥H7N3攻毒提供100%保护并减少排毒。
- rFPV-H7/2155疫苗组全部排毒且4天内死亡。
- 墨西哥H7N3毒株持续快速进化,疫苗种子株需频繁更新。
核心结论
- 新型rFPV-H7/3002疫苗对近期墨西哥H7N3高致病性禽流感病毒提供完全保护,而旧疫苗无效。
研究设计与样本
- 鸡接种两种重组禽痘病毒疫苗(rFPV-H7/3002含2015年H7 HA基因,rFPV-H7/2155含2002年H7 HA基因),三周后以A/chicken/Jalisco/CPA-37905/2015攻毒。
主要发现
- rFPV-H7/3002组对死亡和发病提供100%保护,并显著降低呼吸道和胃肠道排毒滴度。
- rFPV-H7/2155组和对照组100%排毒且排毒滴度更高,攻毒后4天内全部死亡。
- rFPV-H7/3002组攻毒前15/20、攻毒后20/20血清用攻毒病毒抗原经血凝抑制试验可检出抗体。
- rFPV-H7/2155组仅3/20血清抗体与攻毒株反应,但20/20与同源疫苗抗原反应。
- 分子分析显示墨西哥H7N3株自2012年以来持续快速进化,攻毒病毒HA球状头部出现三个潜在新N-糖基化位点。
关键数值与推荐
- rFPV-H7/3002组:100%保护,攻毒前15/20、攻毒后20/20血凝抑制抗体阳性(用攻毒病毒抗原)。
- rFPV-H7/2155组:3/20血清与攻毒株反应,20/20与同源疫苗抗原反应,攻毒后4天内100%死亡。
- 对照组:100%排毒且4天内死亡。
临床怎么用
- 针对H7高致病性禽流感,应选用与当前流行株抗原匹配的疫苗种子株。
- 需持续监测流行株抗原漂移并频繁更新疫苗种子株以维持长期有效控制。
局限性
- 研究仅基于实验鸡攻毒模型,结论外推至田间需谨慎。
- 糖基化位点变化与免疫逃逸的关联基于计算机模拟,未实验验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Since 2012, H7N3 highly pathogenic avian influenza (HPAI) has produced negative economic and animal welfare impacts on poultry in central Mexico. In the present study, chickens were vaccinated with two different recombinant fowlpox virus vaccines (rFPV-H7/3002 with 2015 H7 hemagglutinin [HA] gene insert, and rFPV-H7/2155 with 2002 H7 HA gene insert), and were then challenged three weeks later with H7N3 HPAI virus (A/chicken/Jalisco/CPA-37905/2015). The rFPV-H7/3002 vaccine conferred 100% protection against mortality and morbidity, and significantly reduced virus shed titers from the respiratory and gastrointestinal tracts. In contrast, 100% of sham and rFPV-H7/2155 vaccinated birds shed virus at higher titers and died within 4 days. Pre- (15/20) and post- (20/20) challenge serum of birds vaccinated with rFPV-H7/3002 had antibodies detectable by hemagglutination inhibition (HI) assay using challenge virus antigen. However, only a few birds (3/20) in the rFPV-H7/2155 vaccinated group had antibodies that reacted against the challenge strain but all birds had antibodies that reacted against the homologous vaccine antigen (A/turkey/Virginia/SEP-66/2002) (20/20). One possible explanation for differences in vaccines efficacy is the antigenic drift between circulating viruses and vaccines. Molecular analysis demonstrated that the Mexican H7N3 strains have continued to rapidly evolve since 2012. In addition, we identified in silico three potential new N-glycosylation sites on the globular head of the H7 HA of A/chicken/Jalisco/CPA-37905/2015 challenge virus, which were absent in 2012 H7N3 outbreak virus. Our results suggested that mutations in the HA antigenic sites including increased glycosylation sites, accumulated in the new circulating Mexican H7 HPAIV strains, altered the recognition of neutralizing antibodies from the older vaccine strain rFPV-H7/2155. Therefore, the protective efficacy of novel rFPV-H7/3002 against recent outbreak Mexican H7N3 HPAIV confirms the importance of frequent updating of vaccines seed strains for long-term effective control of H7 HPAI virus.
引用
- Criado MF, Bertran K, Lee DH, et al. Efficacy of novel recombinant fowlpox vaccine against recent Mexican H7N3 highly pathogenic avian influenza virus. Vaccine. 2019. PMID: 30885512. doi:10.1016/j.vaccine.2019.03.009
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。